NasdaqCM - Nasdaq Real Time Price USD

Avalo Therapeutics, Inc. (AVTX)

10.60

-0.22

(-2.03%)

At close: May 14 at 4:00 PM EDT

10.54

-0.06

(-0.57%)

After hours: May 14 at 7:48 PM EDT

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-00

GlobeNewswire yesterday

AVTX
-2.03%
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a

GlobeNewswire last month

AVTX
-2.03%
TRML
Avalo Reports 2023 Financial Results and Provides Business Updates

Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 millionTopline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end

GlobeNewswire last month

AVTX
-2.03%
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:

GlobeNewswire last month

SLRN

AVTX
-2.03%
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company’s existing trading symbol “AVTX”. The Company is implementing the reverse stock split

GlobeNewswire 4 months ago

AVTX
-2.03%
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Annual Meeting has been adjourned until December 20, 2023Most stockholders can vote via proxyvote.com or by calling 1-800-690-6903. If you have any questions about how to vote, please call 1-800-607-0088 WAYNE, Pa. and ROCKVILLE, Md., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) encourages its stockholders to participate actively in the upcoming adjourned annual meeting of stockholders, initially convened on December 5, 2023, and scheduled to reconvene on Wednesday,

GlobeNewswire 5 months ago

AVTX
-2.03%
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Successfully eliminated $35 million debt paving the way for future growth and innovationDivested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed improved cash of approximately $10.2 million as of September 30, 2023 WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2023.

GlobeNewswire 6 months ago

AVTX
-2.03%
Avalo Completes Divestiture of AVTX-800 Series

WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG). The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG

GlobeNewswire 6 months ago

AVTX
-2.03%
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (Nasdaq: HRZN). This significant milestone not only signifies the company's steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug c

GlobeNewswire 7 months ago

AVTX
-2.03%
HRZN

HTFB
Avalo Enters into Agreement to Divest AVTX-800 Series

WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series). AUG will pay an upfront payment of $150,000, as well as, for each compound, make a contingent milestone payment of $15

GlobeNewswire 7 months ago

AVTX
-2.03%
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. The pre-recorded presentation will be made available on Monday, September 11, 2023 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the “News/Events” page in t

GlobeNewswire 8 months ago

AVTX
-2.03%
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong target engagementDisclosed cash of approximately $6.3 million as of June 30, 2023 WAYNE, Pa. and ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2023. “Althoug

GlobeNewswire 9 months ago

AVTX
-2.03%
Avalo to Participate in SVB Securities Therapeutics Forum

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities Therapeutics Forum being held Tuesday, July 11th – Wednesday, July 12th, 2023 in New York, NY. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that targ

GlobeNewswire 10 months ago

AVTX
-2.03%
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels AVTX-002 significantly reduced serum LIGHT levels for study duration indicating target engagement AVTX-002 demonstrated a favorable safety and tolerability profile Additional analyses are ongoing to inform path forward in asthma and potentially other inflammatory condition

GlobeNewswire 10 months ago

AVTX
-2.03%
Avalo to Present at the Jefferies Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 11:00 a.m. ET at the Marriott Marquis in New York, NY. A live webcast of the presentation can be accessed under the “News/Events” page in the Investors section of the Company's website at www.avalotx.com. About Avalo Therap

GlobeNewswire 11 months ago

AVTX
-2.03%
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

Avalo’s SAB is comprised of key opinion leaders in immunology and the LIGHT-signaling network WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company’s Scientific Advisory Board (SAB). The SAB, which is led by Dr. Carl Ware, provides strategic and scientific guidance to Avalo as it progresses its pipeline of therapies that target the LIGHT-signaling network, notably

GlobeNewswire 11 months ago

AVTX
-2.03%

Performance Overview

Return	AVTX	S&P 500
YTD	+16.48%	+10.00%
1-Year	-98.20%	+27.22%
3-Year	-99.84%	+27.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avalo Therapeutics, Inc. (AVTX)

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Avalo Reports 2023 Financial Results and Provides Business Updates

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Avalo Completes Divestiture of AVTX-800 Series

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Avalo Enters into Agreement to Divest AVTX-800 Series

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Avalo to Participate in SVB Securities Therapeutics Forum

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Avalo to Present at the Jefferies Healthcare Conference

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

Performance Overview